AU2023219773A1 - Interleukin-2 muteins for the treatment of autoimmune diseases - Google Patents

Interleukin-2 muteins for the treatment of autoimmune diseases Download PDF

Info

Publication number
AU2023219773A1
AU2023219773A1 AU2023219773A AU2023219773A AU2023219773A1 AU 2023219773 A1 AU2023219773 A1 AU 2023219773A1 AU 2023219773 A AU2023219773 A AU 2023219773A AU 2023219773 A AU2023219773 A AU 2023219773A AU 2023219773 A1 AU2023219773 A1 AU 2023219773A1
Authority
AU
Australia
Prior art keywords
fold
amino acid
seq
agent
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023219773A
Other languages
English (en)
Inventor
Nicole AKRAMOFF
Diane MA
Mohit Mathur
David William Oldach
Asher Schachter
Michaela Schultz
Susan Sloan
William C. TUBBS
Jill YARBROUGH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Visterra Inc
Original Assignee
Visterra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visterra Inc filed Critical Visterra Inc
Publication of AU2023219773A1 publication Critical patent/AU2023219773A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2023219773A 2022-02-11 2023-02-10 Interleukin-2 muteins for the treatment of autoimmune diseases Pending AU2023219773A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263309293P 2022-02-11 2022-02-11
US63/309,293 2022-02-11
PCT/US2023/062395 WO2023154870A1 (en) 2022-02-11 2023-02-10 Interleukin-2 muteins for the treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
AU2023219773A1 true AU2023219773A1 (en) 2024-08-01

Family

ID=85476118

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023219773A Pending AU2023219773A1 (en) 2022-02-11 2023-02-10 Interleukin-2 muteins for the treatment of autoimmune diseases

Country Status (10)

Country Link
US (1) US20230390360A1 (cg-RX-API-DMAC7.html)
EP (1) EP4475875A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025506173A (cg-RX-API-DMAC7.html)
KR (1) KR20240148001A (cg-RX-API-DMAC7.html)
CN (2) CN120346304A (cg-RX-API-DMAC7.html)
AU (1) AU2023219773A1 (cg-RX-API-DMAC7.html)
CA (1) CA3243493A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024009868A (cg-RX-API-DMAC7.html)
TW (1) TW202400218A (cg-RX-API-DMAC7.html)
WO (1) WO2023154870A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
CA3203977A1 (en) 2020-12-04 2022-06-09 Visterra, Inc. Methods of using interleukin-2 agents
TW202333772A (zh) 2021-12-01 2023-09-01 美商威特拉公司 使用介白素-2藥劑之方法
WO2026154422A1 (en) * 2025-01-17 2026-07-23 Otsuka Pharmaceutical Company, Ltd. Il-2-fc fusion protein for use in treating autoimmune diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL304950A (en) * 2015-04-10 2023-10-01 Amgen Inc Interleukin for the expansion of myotonic control T-2 cells
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
CA3032820A1 (en) 2016-08-02 2018-03-22 Visterra, Inc. Engineered polypeptides and uses thereof
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof

Also Published As

Publication number Publication date
KR20240148001A (ko) 2024-10-10
TW202400218A (zh) 2024-01-01
CA3243493A1 (en) 2023-08-17
JP2025506173A (ja) 2025-03-07
EP4475875A1 (en) 2024-12-18
CN120346304A (zh) 2025-07-22
CN119013034A (zh) 2024-11-22
MX2024009868A (es) 2024-08-20
WO2023154870A1 (en) 2023-08-17
US20230390360A1 (en) 2023-12-07

Similar Documents

Publication Publication Date Title
JP7483857B2 (ja) インターロイキン-2作用物質およびその使用
US20250186539A2 (en) Methods for treating cancer
EP4475875A1 (en) Interleukin-2 muteins for the treatment of autoimmune diseases
TWI812918B (zh) IL-7Rαγc結合化合物
US12098178B2 (en) Methods of using interleukin-2 agents
TW202142559A (zh) IL-7Rα結合化合物
US20220226442A1 (en) Interleukin-2 agents and uses thereof
JP2022507606A (ja) Il-7タンパク質と免疫チェックポイント阻害剤の組み合わせで腫瘍を治療する方法
HK40124714A (en) Interleukin-2 muteins for the treatment of autoimmune diseases
HK40113125A (en) Interleukin-2 muteins for the treatment of autoimmune diseases
WO2025125652A1 (en) Combination therapy for use in treating cancer